Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple estrogen treatment sharpen the view for cervical cancer screening?

NCT ID NCT05283421

Diagnosis Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether applying vaginal estrogen before a colposcopy helps doctors see the cervix more clearly in women aged 50 and older. As women age, the area where precancerous changes occur can become harder to view, which may lead to missed diagnoses or repeat procedures. Half of the participants will receive estrogen and half a placebo before their exam, and the study will compare how well the transformation zone is visualized and biopsied. The goal is to see if this simple step can make cervical cancer diagnosis more accurate and timely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vaginal estrogen (Vagifem) or placebo given before colposcopy
What this could lead to
If it works, this simple pretreatment could make colposcopy more accurate for older women, reducing missed diagnoses and unnecessary procedures.
What could go wrong
The benefit is uncertain and may not apply to all women. Side effects from estrogen are possible, and the trial is relatively small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Postmenopausal (defined as no bleeding ≥1 year) women referred for colposcopy aged ≥ 50 years. * Women referred for colposcopy due to a positive HPV test and/or an abnormal cervical cytology. * Women referred for colposcopy due to previous abnormal cervical histology with minimum 6. months since last colposcopy with biopsies. Exclusion Criteria: * Use of estrogen within the last 3 months regardless of administration form. * previous cervical radiotherapy, cervical amputation and/or cone biopsy * pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical intraepithelial neoplasia Uterine Cervical Neoplasms cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Gynecology and Obstetrics

    RECRUITING

    Randers, 8930, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.